Lee · Experimental neurology 2001 · controlled laboratory animal study · n=?

Streptozotocin-induced diabetes causes metabolic changes and alterations in neurotrophin content and retrograde transport in the cervical vagus nerve.

Cited 57 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Animal research

PubMed 11421592 · doi:10.1006/exnr.2001.7673 · record verified 2026-08-27

What was done

Researchers examined metabolic changes, neurotrophin levels (nerve growth factor [NGF] and neurotrophin-3 [NT-3]), and axonal transport in the cervical vagus nerves of streptozotocin (STZ)-induced diabetic rats compared with nondiabetic controls and insulin-treated diabetic rats. Evaluations were conducted at 8, 16, and 24 weeks post-induction. Metabolic alterations were assessed via hexose (glucose, fructose) and polyol (sorbitol) concentrations. Neurotrophin transport was evaluated using a double-ligation nerve model.

What was found

The abstract reports no numerical values. STZ-induced diabetes caused increases in vagus nerve hexose and sorbitol levels that were normalized by insulin treatment. Intact vagus nerve NGF content was increased in diabetic rats at 8 and 16 weeks, returning toward baseline by 24 weeks, whereas NT-3 content was unchanged. Retrograde axonal transport of both NGF and NT-3 was significantly reduced at later disease stages (16 and 24 weeks). Anterograde transport of NGF or NT-3 was not detectable in control or diabetic vagus nerves.

Why it matters

This study demonstrates that experimental diabetes impairs retrograde neurotrophin transport in the vagus nerve, suggesting that neurotrophin deprivation may contribute to diabetic autonomic neuropathy.

Limits

The study was conducted exclusively in a chemical rat model of diabetes (STZ), which may not replicate human diabetic autonomic neuropathy. The abstract does not provide exact animal numbers, numerical concentrations, transport rates, or statistical effect sizes.

Cited by